Lantheus Holdings, Inc.

Good morning. Welcome to the Lancia's third quarter 2024 conference call. All lines have been placed on mute. This call is being recorded, and a replay will be available in the investor section of the company's website approximately two hours after the completion of the call and will be archived for at least 30 days. I'll now turn the call over to Mark Narni, Vice President of Investillations. Mark?

Thank you. Good morning. With me today are Brian Markison, our CEO, Paul Blanchfield, our president, Bob Marshall, our CFO, Jeff Humphrey, our chief medical officer, and Amanda Morgan, our chief commercial officer. We will begin with prepared remarks and then open the call for Q&A. This morning, we issued a press release, which was furnished to the SEC under Form 8K, reporting our third quarter 2024 results. The release and today's slide presentation are in the investor section of our website. Any comments made could include forward-looking statements. Actual results may differ materially from these statements due to a variety of risks and uncertainties which are detailed in our SEC filings. Discussions will also include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is included in the investor section of our website. I will now turn the call over to our CEO, Brian.

Thank you, Mark, and good morning, everyone. Lantheus is the leading radiopharmaceutical-focused company with market-leading commercial products and a growing radiopharmaceutical pipeline targeting areas of significant unmet need. In the third quarter, we continue to enhance our leadership and create long-term sustainable growth through operational excellence, financial discipline, and prudent capital deployment. Polarify, our PSMA PET imaging agent, delivered solid performance and remains on track to reach blockbuster status in 2024. And DFINITY, our ultrasound enhancing agent, grew double digits year over year. The continued success of these flagship diagnostic agents enables us to invest both organically and inorganically in our pipeline to extend our radiopharmaceutical leadership and create long-term value for shareholders. Before we move on to review the quarter, I'd like to commend CMS for its landmark decision to pay separately for specialized diagnostic radiopharmaceuticals beginning January 1, 2025. Under the hospital's outpatient prospective payment system, or OPPS rule, this is a significant win for patient access and will ensure specialized diagnostic radiopharmaceuticals, including Polarify, are accessible for Medicare fee-for-service patients going forward, while also supporting long-term innovation in the field, including potentially MK6240 and NAV4694, our late-stage diagnostic product candidates for Alzheimer's disease. With that, I'll now turn the call over to Paul to provide an operational update.